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ABSTRACT 
Bone Fracture Toughness of Estrogen Deficient Rabbits 
 
Matthew S. Smith 
 
Bone mass is commonly used as an indicator of fracture risk.  It has been shown in 
numerous studies that bone loss causes increased bone fragility and risk of fracture.  It has also been 
shown that 50% of patients with osteoporotic vertebral compression fractures have the same bone 
mass as normal age matched controls.  Thus, bone mass alone is not the only indicator of bone 
quality and ability to resist fracture. 
The objective of this study was to qualitatively assess bone’s mechanical and 
histomorphometric changes with drug treatment, and estrogen deficiency, using fracture toughness, 
femoral neck fracture and histomorphometric analysis in an ovarectomized rabbit model.   
No significant differences were found in fracture toughness, porosity, or femoral neck 
ultimate strength for any treatment group, which may have be from a lack sufficient time for the 
difference caused by estrogen deficiency and drug treatment to manifest in the rabbit model.
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NOMENCLATURE 
General: 
 
ACUC: Animal Care and Use Committee 
ASTM: American Society of Testing Mechanics 
BMC: Bone Mineral Content 
BMD: Bone Mineral Density 
CT: Compact Tension 
DEXA: Dual Energy X-ray Analysis 
EIA: Energy Information Administration 
FDA: Food and Drug Administration 
Fem: Fem(ur)(oral) 
Fx: Fracture 
GDP: Gross Domestic Product 
ID: Internal Diameter 
L-spine: Lumbar Spine 
N: Number (of specimens) (of patients) 
NaCl: Saline Solution 
NIH: National Institute of Health 
NS: Normal Saline 
OSU: Ohio State University 
Ovx: Ovariectomized  
Ris: Residronate 
SD: Standard Deviation 
 
Fracture Toughness: 
 
a: Length from hole center to crack tip in fracture toughness specimen 
B: Specimen thickness 
C: Compliance 
EPFM: Elastic Plastic Fracture Mechanics 
F: Work from External Forces 
f(a/W): Shape Factor 
G: Strain Energy Release Rate 
K: Stress Intensity Factor 
Kc: Critical Stress Intensity Factor 
LEFM: Linear Elastic Fracture Mechanics 
Pc: Critical Force or Load 
Pmax: Maximum load 
r: Radial Distance 
R/F: Resorption/ Formation 
σ: Stress 
T: Thickness of fracture toughness specimen 
U: Total Energy 
Ua: Internal Strain Energy 
  - x - 
Uγ: Elastic Surface Energy 
Uo: Initial Energy 
W: Width of fracture toughness specimen 
 
Histomorphometric Variables 
 
CtAr: Cortical Area  
%CtAr: Percentage Cortical Area 
Hn.Cn.Ar: Haversian Canal Area 
MeAr: Medullary Area 
OAr: Osteoid Area 
OnAr: Osteon Area 
OnD: Osteon Density 
OnN: Osteon Number 
OnPm: Osteon Perimeter 
Po: Porosity 
TtAr: Total Bone Area 
V.Cn.Ar: Volksmann Canal Area 
Po.Ar: Pore Area 
 
Compositional Analysis 
 
AW: Ashed Weight 
DW: Dry Weight 
V:  Volume 
WW: Wet Weight 
 
Measurements 
 
Å: Angstroms 
oC: Degrees Celsius 
cm: Centimeter 
kg: Kilogram  
min: Minutes 
mm: Millimeter 
µm: Micrometer 
mg: Milligram 
ml: Milliliter 
µg: Microgram 
N: Newton 
psi: Pounds per Square Inch 
RPM: Revolutions Per Minute 
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CHAPTER 1: INTRODUCTION 
1.1 Project Overview  
Bone is in a constant state of change with the processes of remodeling and modeling, 
which is different from the growth process, since it is an overturning and renewal of a mature 
skeleton.  As a bone models and/or remodels it becomes more porous, but may have an 
increase in overall bone mass.  Due to this unique property, fracture toughness, a well known 
engineering measure of a predamaged material’s resistance to fracture or crack propagation, 
is a good indicator of bone quality.  
Bone mass is commonly used as an indicator of fracture risk, and Dempsey and Linsey 
(1993) have shown that bone loss causes an increased risk of fracture and fragility in general, 
but Avioli (1987) has reported that 50% of people with osteoporotic vertebral compression 
fractures have the same bone mass as normal age matched controls.  This would imply that 
bone mass is insufficient as an indicator of bone quality and ability to resist fracture. 
The purpose of this project is to qualitatively assess the fragility of bone by use of 
histomorphometry and fracture toughness testing, as well as bone mineral density testing 
(DXA), to demonstrate the ability of bisphosphonates to decrease the fragility, or maintain 
the fragility at a pre-ovarectomized state. 
1.1.1 The Cost of Osteoporosis 
 
The National Institute of Health estimates that the annual cost of  osteoporitic and 
associated fractures in the United States to be $17 billion, or $47 million per day (NIH, 
2003).  The annual cost is approximately 0.2% of the United States Gross Domestic Product 
(GDP) for the year 2000, which is greater than the 2000 GDP of such countries as Costa Rica 
($14.7 billion), El Salvador ($11.0 billion), and Oman ($16.7 billion) (EIA, 2002).  The 
  - 2 - 
number of hip fractures, which is the second most common osteoporotic fracture, has been 
estimated to rise to 6 million per year by 2050 (Genant et al, 1999).   
1.1.2 Clinical Significance 
 
Osteoprosis is a major problem for approximately 44 million Americans, 68% 
of whom are women.  Half of woman with osteoporosis sustain some kind of 
osteoporitic fracture (Stevenson, 1990).  One out of two women and one out of eight 
men over the age of fifty will have a fracture related to osteoporosis.  The annual 
fracture total is approximately 1.5 million with : 300,000 hips, 700,000 vertebral 
fractures, 250,000 wrists, and 300,000 other fractures, such as ribs, shoulders, etc.  
The breakdown of these fractures can be seen in figure 1 (NIH, 2003). 
Hip
19%
Vertebral
46%
Wrist
16%
Other
19%
 
Figure 1.1.2-1: Fracture Types and Percentages Related to Osteoporosis (adapted from NIH 
ORBD data) (NIH, 2003) 
 
Cortical bone fragility has been implicated in debilitating conditions such as 
osteoporitic fracture, fatigue fracture, stress fracture, and loosening of prosthesis, and 
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the loss of cortical bone has been identified as a key feature contributing to femoral 
neck fracture. 
Crabtree et al. (2001) concluded from a study of intracapsular hip fracture 
patients that generalized bone loss accounts for less than about 15% of fracture risk 
and that a loss of cortical bone thickness and increased intracortical porosity is the 
key feature to hip fracture risk. 
1.2 Objectives 
To better understand the effects of estrogen deficiency and various treatments for 
osteoporosis on the fracture toughness of bone, three objectives were set: 
1. Perform histomorphometry to quantify bone parameters (porosisty, osteon density, 
osteon area, etc) for comparison. 
2. Perform mechanical testing (fracture toughness and femoral neck fracture) on the 
bones to find strength and toughness values for comparison. 
3. Compare and correlate the histomorphometric and mechanical data. 
1.3 Hypotheses 
The following hypotheses were made: 
1. There is a significant difference in fracture toughness between all 
Ovarectomized (Ovx) and Normal specimens. 
2. There is a significant difference in the fracture toughness between Ovx and 
Ovx with Residronate (Ovx – Ris) treatment specimens, with the Ovx-Ris  
specimens approaching but not reaching the fracture toughness of the Normal 
group. 
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3. There is a significant difference in the structural properties of the femoral 
neck between the groups, with the values of the Ovx-Ris treatment group 
approaching that of the Normal group. 
4. There is a significant difference in the dynamic and static histomorphometric 
that will correlate with the fracture toughness and femoral neck fracture 
values, with the Ris group approaching the values of the Normal group.  
1.4 Anatomical Background 
Bones are the main structural components of the body.  They provide support 
for the weight of the body, resist dynamic loads caused by the movement of the body, 
protect the nervous system and organs, provide levers for the skeletal muscles, and 
are reserves for various substances necessary for bodily function, such as calcium.  
The skeleton does all of these things with a high level of adaptability, making the 
skeleton a machine of unparalleled complexity.  From an engineering or design 
standpoint, it would be difficult to imagine creating a structure which satisfies these 
needs, and even more difficult to create such a structure.   
Bone is a unique material.  Unlike most engineering materials, it cannot be 
considered homogeneous, bone is often assumed to be transversely isotropic, which is 
similar to many composite materials.  Unlike all engineering materials, it has the 
ability to repair damage and adapt to various loading situations, using a constant state 
of tearing down and renewal, through resorption and formation.    
1.4.1 Body Definitions 
 It is beneficial to know some of the anatomical terms that will be used in this 
paper particularly in chapters 4 and 5.  These terms are general directional, sectional, 
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and location terms, and although they are not related to engineering, they are 
necessary in the study of anatomy and physiology. 
 Figure 1.4.1 shows the important planar definitions for the rabbit and most 
quadrupeds, which have some notable differences to bipeds, such as humans. 
 
Figure 1.4.1 – 1: Schematic representation of anatomical terms for the rabbit (Wingerd, 
1985). 
 
 The dorsal side is simply the back side.  The reader may notice that the dorsal 
and superior sides are equivalent for a quadruped, but are not the same for a biped (ie   
humans); this may cause some confusion for those familiar with only human   
anatomy.  The anterior (cranial), caudal (posterior), and ventral (inferior) sides may 
also cause confusion, because the terms are the same, as shown for a quadruped, but 
do not correspond for bipeds.  The difficulty can be eliminated by thinking of the 
directions (superior, inferior, cranial, and caudal) separately from the planes (anterior, 
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posterior, dorsal, and ventral).  For example, dorsal means the plane of the back, and 
can be easily seen as the plane looking down on the top of the animal, if the animal is 
standing normally.  The superior direction is simply that it is above another structure, 
this is not related to body structure, per se, and just means to be above something 
else.  The other pairs of correlating planes and directions make sense as well, when 
thought of in this way. 
 
Figure 1.4.1-2: Diagram of the rabbit skeleton (Wingerd, 1985). 
 
 Figure 1.4.1-2 shows the rabbit skeleton.  The bones used in this study were 
the tibia and femur, which are the two main long bones of the hind legs of the rabbit.  
The fibulas were also removed during the dissection, because unlike humans, they are 
fused to the tibias, but were eventually discarded during machining. 
Bone anatomy necessitates the definition of more terms.  This project uses the 
femur and tibia, so the effort of definition will focus on these.  Proximal is a 
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direction, relative to a particular point, going towards the midpoint of the body. By 
this definition, the proximal end of a long bone would be the end that is towards or 
closest to the midpoint, which for the femur would be the head and neck region, and 
for the tibia it would be the condyles that make up part of the knee.  The midshaft of a 
long bone is the general area that is approximately halfway between the two end 
points of the long bone, which is often thought of as a shaft even though it does not 
usually have the uniform cylindrical shape associated with a shaft.  The term 
definitions can be seen in figures 1.4.1-3 and 1.4.1-4, where the arrows are indicative 
of the directional definition from the midshaft. 
  
Figure 1.4.1-3: Definition of locations and Anatomy of the Femur (Wingerd, 1985) 
 
Mid-shaft
Proximal
Distal
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Figures 1.4.1-3 and 1.4.1-4 also show some of the important bony landmarks 
of the femur and tibia. 
 
 
Figure 1.4.1-4: Direction and Anatomy Illustration of the tibia (Wingerd, 1985) 
 
1.4.2 Macrostructure of Bone 
 Macroscopically bone is generally divided into two types: cortical and 
trabecular bone.  Cortical bone is often referred to as compact bone, and trabecular 
bone is known as cancellous or spongy bone.  The different types of structures can 
easily be seen in the figure 1.4.2-1, where cortical bone is the dense region and 
cancellous is the latticework region, that makes up most of the femoral head and 
neck, with a outer cortex of cortical bone, but the shaft is mainly cortical bone.  
Mid-shaft
Proximal
Distal
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Figure 1.4.2-1: Cross-section of the Proximal Femur Showing Cortical and Cancellous Bone 
(Albright and Skinner, 1987, with labels added) 
 
 The structure of having a compact outer shell with an inner woven structure 
allowing for optimal mechanical function under loading is common in all bones.  The 
structure of bone adapts to the loading that the bone is subjected. 
1.4.3 Microstructure of Bone 
Microscopically, two types of bone can be distinguished, woven and lamellar 
bone.  Woven bone is characterized by an irregular array of loosely packed collagen 
fibrils resembling a crudely woven cloth.  This type of bone is initially formed in the 
Cortical 
Bone 
Trabecular 
Bone 
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embryo and during child development, but is only found in small amounts in the adult 
skeleton, except under conditions of rapid bone formation, such as fracture healing 
and diseases such as Paget’s disease.   In the normal adult skeleton, both the cortical 
and trabecular bone is made of parallel collagen fibers, organized in a lamellar 
pattern. 
 Bone consists of two major components: the matrix of collagen fibers and four 
types of bone cells.  The matrix is the main structural referent of the bone, which has 
a characteristic distribution.  The outer part of the bone consists of a shell or cortex of 
cortical bone that generally forms the overall conformation of the bone and within 
this structure lays the trabecular bone. 
 The cortical bone is divided into three regions.  The outer most region is 
known as periosteal bone.  The middle and most dominant region is the Haversian 
bone, which is a region of bone containing the Haversian system, and the inner layer 
called subcortical bone. 
 Haversian bone consists of hollow cylinders made of concentric lamellae with 
a vascular canal in the center, which is called an osteon.  The diameter of an osteon is 
approximately 200 µm regardless of species, because the maximal transport distance 
for nutrients is approximately 100 µm.   
The Bone Matrix 
 Bone matrix has four major molecular components: collagen, noncollagenous 
proteins, nonprotein organic material, and mineral crystals resembling 
hydroxyapatite, with the chemical structure Ca10(PO4)6(OH)2. 
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 Collagen is the most abundant organic protein making up 90% of the organic 
matrix.  The collagen fibers are bundled into a complex three-dimensional structure 
similar to rope that form a lamellae with the collagen fibers running parallel, with the 
long axis being at right angles in adjacent lamellae. Collagen has a triple helix 
structure, which can be though of as like a rope, which gives bone its tensile strength. 
 
Figure 1.4.3-1: Composition of Cartilage, Fibrocartilage, and Bone (Albright, ). 
 
 The remainder of the organic matrix is closely associated with the collagen 
fibers and is dependent on the orientation of the collagen fibers.  The noncollagenous 
proteins 
 Mineral makes up approximately 65% of the dry weight of bone, and is made 
of very small crystals of the dimensions 200-400 x 35-75 x 10-40 Ǻ in the shape of 
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plates.  These plates are located within and between the collagen fibers in such a way 
to give the bone its compressive strength and stiffness, which is similar to a chopped 
fiber composite. 
 The minerals are laid down during formation of new bone.  Such substances 
as calcein, tetracycline, polyphosphates, and bisphosphonates have an affinity for 
calcium phosphate, and are laid down in areas of new bone formation.  This property 
is what makes marking for dynamic histomorphometry possible, which will be 
explained in later chapters. 
Osteoclasts 
Osteoclasts are multinucleated cells and are known to be the primary cell 
responsible for bone resorption, or the breakdown of bone.  The task of resorbing 
bone is accomplished within a closed microenvironment, which is between the cell 
and the bone surface, as can be seen in figure 1.4.3-2. 
Osteoclasts have proton pumps on the side attached to the bone, which is 
called the ruffled border.  The osteoclast can be thought of as an upside down cup on 
a saucer, which leaves a space between the bone and the cell.  The proton pumps of 
the osteoclast pumps protons into this enclosed space, which causes an enclosed 
acidic region (pH of approximately 4) that dissolves the bone matrix.  The cell also 
pumps various enzymes into the enclosed space as well, such as cathespins, and 
possibly collegenase, which dissolves the collagen matrix. 
There are three main ways of controlling bone resorption, which are: 
recruitment of new osteoclasts, lifespan of new osteoclasts, which is determined by 
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apoptosis, and the regulation of the mature osteoclasts.  All three of these processes 
seem to be influenced by cells of the osteoblastic lineage. 
 
Figure 1.4.3-2: Diagram of an osteoclast (Fleisch, 2000, with additional label)  
 
 
Figure 1.4.3-3:  Role of Osteoblastic cells on Osteoclast’s and therefore bone resorption 
(Fleisch, 2000). 
 
Microenvironment 
with ruffled edge 
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These cells are varied in size and are characteristically seen in lacunae of 
resorbed bone.   
Osteoblasts 
Osteoblast comes from the two Greek words osteon, which means bone, and 
blastos, which means germ.  Osteoblasts are mononucleated cells and are primarily 
responsible for bone formation, or rather the synthesis of the organic components of 
the bone matrix (i.e. type I collagen, proteoglycans, and glycoproteins). Osteoblasts 
are derived from mesenchymal progenitors, and lay down the unidirectional organic 
matrix, which is later mineralized.   
The time between the laying down and calcification steps means that there is a 
layer of uncalcified bone under the osteoblast.  The uncalcified seam that is left by the 
osteoblast is thin when bone formation rate is decreased, and it is widest when 
mineralization is delayed.  
The osteoblasts can be found on the bone surface and have the appearance of 
epithelium, which is why they are often classified as bone lining cells, when they are 
inactive. 
Bone Lining Cells 
Active osteoblasts and bone lining cells form a membrane on the bone 
surface. Bone lining cells are osteoblasts that are not actively forming bone.  When 
the osteoblast is inactive, they are flat and found on the bone surface.  The inactive 
osteoblasts are called bone lining cells because of the characteristic of osteoblasts 
appearing like epithelial cells, which are lining cells in the gastrointestinal track. 
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Osteocytes 
Osteocytes are the osteoblasts that have been completely embedded in the 
bone matrix.  Osteocytes are the most abundant cell found in bone, but their exact 
purpose is still poorly understood.  These cells are in the lacunae and are connected to 
each other and to osteoblasts.  It is theorized that there is signaling between bone 
cells, and that osteocytes are the cells that sense the mechanical stimulation. 
1.5 Bone Modeling and Remodeling 
 
 The skeleton serves many mechanical, metabolic, and protective 
functions.  The most obvious functions are mechanical support and protection. Bones 
are often mistakenly thought of as dead or unchanging structures, but bone is a living, 
metabolically active, and highly organized tissue that is in a constant state of flux 
through processes of resorption and formation.  The osteoblasts and osteoclasts are in 
opposition to each other in a cycle called the resorption/ formation cycle (R/F).  The 
rate of these processes lends itself to this widely held misconception, because the 
processes are too slow, or too imbalance for them to be seen macroscopically, with 
the naked eye, except over a long period of time and/or some disease state. 
Both cortical and cancellous bone undergoes remodeling, in which old bone is 
torn down or resorbed, and new bone is built of formed in its place.  This process is 
very important in damage repair, and in keeping the skeleton strong.  It is very 
important in the bones adaptation to loading, since the bones will reform in a new 
architectural formation to most optimally handle the loading environment, or the 
particular loading parameters present on the bone. 
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In adults, bone remodeling accounts for more than 90% of normal bone 
turnover.  In normal individuals, the remodeling space is approximately 6-8% of 
skeletal volume (Parfitt, 1980). 
1.5.1 R/F Balance Implications in Bone Fragility 
 
  The resorption/ formation balance is significant in the net amount of bone 
mass and/or microstructructural changes, such as porosity. 
Normal bone has a balance between the amount of bone being resorbed and 
the amount being formed, for a net change of approximately zero.  As people age, the 
osteoclasts start to slightly outpace the osteoblasts, so skeletal mass decreases, thus 
fracture risk increases.  Diseases such as osteoporosis are from an imbalance of this 
process.  The R/F balance is particularly skewed in women after menopause. 
1.5.2 Bone Mass and Bone Fragility 
 
Many studies have shown that bone, rather human or other animal, from 
disuse (paralysis, suspension, immobilization, etc.) and/or sex hormone deficiency 
(ovarectomy or oophorectormy) results in loss of bone mass (Smith 1989;Weinreb, 
1989; Saville, 1969; Schoutens, 1984; Wronski, 1985; Okumra, 1986; Bain, 1990; 
Cao, 2001).  Decreased bone mass in humans has been shown to be an indicator of 
increased fracture risk (Dempster, 1993), but Avioli (1987) has reported that 50% of 
osteoporotic vertebral compression fractures have the same bone mass as normal age 
matched controls. 
Bone mass is not the only change in bone during resorption and formation.  
The architecture of the bone is also changed.  Patients with osteoporotic fractures are 
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found to have larger osteons with larger Haversian canals and a lower osteon density 
than patients without a fracture (Barth 1992).  The change in structure at a 
microscopic level may not be seen in the current tests available for bone mineral 
density or bone mass testing, so a new technique is needed to test for fracture risk. 
 
1.6 Bisphosphonates 
Various drugs have been used for the treatment of osteoporosis.  Two of the 
major categories of treatment are Parathyroid Hormone, Hormone Replacement 
Therapy, and Bisphosphonates.  This project focuses on the use of bisphosphonates, 
because of their widespread use, FDA approval for osteoporosis prevention and 
treatment, and the proven safety and effectiveness in clinical trials. 
The first report of the biological characteristics of bisphosphonates appeared 
in 1968, from earlier studies of inorganic pyrophosphates (Fleisch, 2000). 
Bisphosphonates, which were formerly called diphosphates, are analogs of 
pyrophosphate, but has a carbon joining the two phosphors instead of an oxygen, as in 
the pyrophosphate.  The carbon is bonded to two other groups to fill it octet and has 
the form shown in figure 1.6.3-1.  The two side groups (R1 and R2) are what make 
each bisphosphonate unique; figure 1.6.3-2 shows the side groups of the FDA 
approved drugs, and their corresponding names and manufactures.   
 
Figure 1.6.3-1 General Chemical Structure 
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Table 1.6.3-1: FDA approved bisphosphonates for the treatment and prevention of 
osteoporosis in postmenopausal women and their chemical structure (Adapted from 
Fleisch, 2000). 
 
Name Brand 
Name 
Manufacture Chemical Structure 
Alendronate Fosamax Ambiogen; 
Merck, 
Sharp & 
Dohme 
 
Residronate Actenol Proctor & 
Gamble 
 
 
 Bisphosphonates are commonly used in the treatment of osteoporosis, 
glucocorticoid-induced osteoporosis, hypercalcemia of malignancy, Paget's disease, 
heterotopic ossification, and osteolytic bone metastases of breast cancer or multiple 
myeloma. 
 There are currently only two bisphosphonates that are FDA approved for the 
treatment of osteoporosis, which are Alendronate and Risedronate, there are four 
other bisphosphonates that are also commonly used in the treatment of bone loss, but 
are not FDA approved for osteoporosis treatment. 
 One drug that is FDA approved for the treatment and prevention of 
osteoporosis in postmenopausal women is risedronate, which is the type of 
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bisphosphonates used in this study.  Several studies have shown that residronate is 
effective in increasing bone mineral density (BMD), as shown in tables 1.6.3-2.  
Several studies have shown the effectiveness of Alendronate and are included in table 
1.6.3-3 for the purpose of completeness. 
Table 1.6.3-2:  Effects of Risedronate Treatment on BMD (adapted from Cummins, et al, 
with additions) 
 
Author N Mean Increase (%) in BMD in Treatment 
Group vs. Placebo 
Harris, et al., 1999 2458 L-spine:                                           4.4 
Femoral Neck:                                2.8 
Reginster, et al, 2000 1226 L-spine:                                           5.9 
Femoral Neck:                                3.1 
Geusens, et al. 1999 9497 L-spine: (2.5 mg dose)                   5.37  
              (5.0 mg dose)                   7.02 
Femoral Neck: (2.5 mg dose)        2.11 
                         (5.0 mg dose)        3.24 
Fogelman, et al, 2000 543 L-spine: (2.5 mg dose)                   1.4 
              (5.0 mg dose)                   4 
Femoral Neck: (2.5 mg dose)        1.9 
                         (5.0 mg dose)        2.3 
Mortensen, et al, 1998 111 L-spine: (5 mg cyclic dose)           2.7 
              (5 mg daily dose)             5.7 
Fleisch, 2000 large L-spine: (5 mg daily dose)         4.3 – 5.8 
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Table 1.6.3-3: Effects of Alendronate on BMD in Postmenopausal Woman (adapted from 
Cummins, et al, with additions) 
 
 The action of Bisphosphonates on the process of bone resorption and 
formation is not well known, but there are theories of how the bisphosphonates effect 
the osteoclasts, which can be regulated by four ways: inhibition of recruitment, 
inhibition of osteoclast adhesion, shortening of the osteoclast lifespan, and/or 
inhibition of the osteoclast activity. 
 
1.7 Validity of the Animal Model 
 
1.7.1 Introduction 
 
 Animals are invaluable assets in medical research, since they allow for the study of 
medical and biological processes in a living system without harming humans.  The use of 
animals allows for the study of things that are impossible, immoral, or unethical to study 
in humans.  For example, chemical exposures are often studied using animals, which 
Author N Mean Increase (%) in BMD in Treatment 
Group vs. Placebo 
Liberman et al, 1995 994 L-spine:                                           8.8 
Femoral Neck:                                5.9 
Black et al, 1996 2047 L-spine:                                           6.1 
Femoral Neck:                                4.1 
Cummings et al, 1998 4432 L-spine:                                           6.6 
Femoral Neck:                                4.6 
Pols et al, 1999 1908 L-spine:                                           4.9 
Femoral Neck:                                2.5 
Hosking et al, 1998 1609 L-spine: (2.5 mg dose)                   3.1 
              (5.0 mg dose)                   4.6 
Total Hip: (2.5 mg dose)               2.2 
                         (5.0 mg dose)        2.7 
McClung, et al, 1998 447 L-spine: (2.5 mg dose)                   6.39 
              (5.0 mg dose)                   7.45 
Total Hip: (2.5 mg dose)                4.09 
                         (5.0 mg dose)         5.41 
Ravn et al, 1999 1609 Femoral Neck:  (5 mg + placebo)   1.6 
                          (5 mg)                    4.3 
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would be considered reprehensible to conducting on humans and would be similar to 
some of the crimes against humanity committed by the Nazis during World War II. 
 The type of study being undertaken often makes the use of animals necessary, but 
great care must be taken in the selection of the animal model and the interpretation of 
these models. 
1.7.2 Interpretation of Animal Model Results 
 
 Animal models, no matter how well selected, are still just models.  A model, 
by definition, is only an approximation of the phenomenon that is desired to be 
studied.  Care and intelligence should be used in the interpretation and 
implementation of results derived from an animal model for applications to humans. 
1.7.3 Selection of an Animal Model 
 
 Care must be taken in the selection of the model, because animal physiology 
is often different from that of humans, and the effect that is desired to be studied in 
humans may be very different in animals.  A simple example of this would be the 
attempted use of a reptile model for the study of body temperature change in humans 
with cold exposure.  A reptile does not have a steady internal body temperature, and 
has no regulation mechanism, but humans do, so the reptile model would be unable to 
model the human phenomenon, because the mechanism desired for study, does not 
exist in the model.  To be able to select an effective animal model, knowledge of the 
phenomenon in humans and the similar phenomenon in animals must be known, or 
some knowledge of the mechanism must be known before the experiment can begin. 
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Many studies (biochemical and radiodensiometric) have established that 
disuse (immobilaztion, paralysis, and weightlessness), and sex hormone deficiency 
causes loss in bone mass (Nestle, 2000; Li, 2001; Yang, 1997; Bain and Rubin, 1990; 
Smith and Gillian, 1989; Weinreb, et al., 1989; Wronski et al., 1985; Okumura, et al., 
1986; Schoutens, et al, 1984; Saville, 1969; Muhlbaur, et al 1971). 
This study used a sex hormone deficient rabbit model that has been shown to 
have the desired biological effects on bone that we wish to study, and the 140 day 
duration will allow for two full remodeling cycles, which should allow sufficient time 
for the observation of change in fragility, if any, with treatment (Mashiba et al., 
2001). 
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CHAPTER 2: FRACTURE TOUGHNESS OF BONE 
 
2.1 Bone as an Engineering Material 
 
 Bone is an anisotropic material.  The material properties depend on several 
factors, such as microstructure (Wagner and Weiner, 1992), density (Behiri and 
Bonfield, 1984) and orientation (Pope and Outwater, 1974).  Correlations between 
strength and fracture toughness, one cannot be predicted from the other (Zioupos and 
Currey, 1998). 
 Bone is often thought of as a composite material.  A composite is a material 
that has at least two distinct materials or phases (matrix and fiber), and bone is often 
thought of in this way, because of the nature of the collagen fibers and minerals. 
2.2 Introduction to Linear Elastic Fracture Mechanics (LEFM) 
 
 Linear Elastic Fracture Mechanics (LEFM) is assumed valid when the plastic 
deformation around the crack tip is small compared to the crack length.  When this 
condition is violated other methods of analysis such as Elastic Plastic Fracture 
Mechanics (EPFM).  The test specimen must be designed such that this condition is 
met for the material being tested. 
 Fracture toughness is the measure of a damaged material to resist the 
propagation of the crack or damage.  This is a good measure for bone, because bone 
is damaged by its very nature.  This is because of the modeling and remodeling cycles 
that cause the lacunar structure, which would be called damage in an engineering 
structure.  Fracture toughness analysis is conducted using an energy balance approach 
or a stress field analysis. 
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2.2.2 Energy Balance Approach 
 The key idea to this approach is that a crack will only grow when there is 
sufficient potential energy in the material to overcome the resitance of the material.  
As the crack extends there is a decrease in elastic strain energy within the stressed 
specimen.  The total energy, U, can be described by the following equation: 
FUUUU ao −++= γ  
where Uo is the elastic energy of the loaded uncracked plate, Ua is the internal strain 
energy, Uγ is the elastic surface energy, and F is the work done by the external force.   
2.2.3 Stress Analysis Approach 
 This technique, as the name implies, analysizes the stresses in the vicinity of 
the crack tip.  The maximum stress intensity at the crack tip before crack extension is 
the critical stress intensity factor and is denoted by Kc.  The stress ahead of the crack 
tip in linear elastic materials is described by: 
( )θ
π
σ ijij fr
K
2
=  
where r is the radial distance from the crack tip and θ is the polar direction from the 
crack tip.  As r increases to r >> 0, the stress becomes zero. 
 For thicknesses smaller than 3 mm a linear relationship exists between KIC2 
and GIC (Wright and Hayes, 1977; Behiri and Bonfield, 1984).  KIC and GIC are 
generally considered to be equivalent measures of fracture toughness, KIC reaches a 
constant value for certain thicknesses, but GIC continues to decrease with increasing 
thickness for the bovine tibia (Norman, et al 1995b).  The lack of a shown constant 
value for GIC in cortical bone with thickness makes KIC an attractive test parameter; 
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even though GIC has been predicted to be a better indicator of composite, such as 
bone, fracture toughness (Grootenboer and Weersink, 1982). 
2.3 Introduction to Fracture Toughness Testing (Stress Analysis Approach) 
 
 Fracture toughness has become a very important field in engineering.  This 
field analyzes materials and structures that are already built, and may not have the 
ideal material and structural properties that were present when the structure was first 
made.  A classic example of fracture toughness analysis is the cracked bridge 
problem.   
 A mechanics of materials approach to the analysis of a flaw is to just model 
the material as if it were a perfect material, only weakened by some factor.  This is 
often a good means of modeling, but a danger inherent in cracks is the potential for 
the crack to propagate suddenly and uncontrollably, particularly in brittle materials. 
 Bone by its very nature, from an engineering standpoint, fits the concept of 
being a “damaged” material, because the bone is under a constant state of crack 
growth and crack repair. 
2.3.1 Modes of Testing 
 
There are three modes of loading, which can be applied singly or in 
combination to a body, labeled as modes I, II, and III.  Mode I is also known as the 
opening mode, in which the crack propagates perpendicular to the applied load.  
Mode II is the sliding of one of the crack faces with respect to the other, which is why 
it is also known as the shear mode.  Mode III is also known as the tearing mode, since 
is it similar to the tearing of a piece of paper, and is valuable in the measure of 
resistance to out-of-plane shear. 
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 Mode I fracture toughness testing was the focus of this paper, so more detail 
will be given for this type. 
 There are several orientations that the fracture toughness specimen can be 
taken from the specimen.  The various orientations are significant in bone, because of 
the linearly isotropic material properties of bone.  Behiri and Bonfield (1989) using 
bovine bone, and Norman, et al (1996) using human bone showed that the crack will 
propagate in the longitudinal direction regardless of the loading direction, which 
would imply that bone is less tough in the longitudinal direction, which is consistent 
with the composite theory of bone and the orientation of the collagen fibers.  The 
shear cracks has been observed to propagate between the lamellae, along the cement 
lines (Saha, 1977; Vashisth, 1997). 
2.3.2 Fracture Mechanics of Composite Materials 
 
 Fracture in composite materials is different than in an isotropic material, 
where the crack will only grow in size.  The fracture of composite materials depends 
on the properties of the phases and also the interface between the phases.  The 
fracture can depend on any of these properties, or a combination of all of them. 
2.3.3 Specimen Dimensions 
 
 The specimen dimensions are very important, since K is thickness dependent, 
with K increasing as the thickness increases, to a maximum and then begins to 
decrease with increasing thickness.  The limiting value of K at plain strain is a 
property independent of size and geometry, which is known as KC, also known as 
fracture toughness or stress intensity factor.  KC uniquely characterizes the crack tip 
conditions, as long as the plastic zone is small. 
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 KIC has been shown to linearly increase with increasing width in compact 
tension specimens machined from bovine bone (Bonfield, et al 1985).  KIC has also 
been found to be independent of thickness for 1.85 mm – 3 mm (Wright and Hayes, 
1977) and for 0.5 mm – 2 mm (Behiri and Bonfield, 1984), which allows for some 
margin of error in machining of specimens.  Although it KIC is independent of the 
specimen thickness at certain ranges, plain strain is achieved at the larger thicknesses, 
so bone fracture toughness values from the literature, and this paper, can not 
generally be represented by plain strain fracture toughness.  Norman, et al in 1991 
determined that the minimum thickness for a 17.5 mm x 16.8 mm CT specimen to 
achieve plane strain conditions for bovine bone was 7 mm, which is difficult to 
achieve in most animals and in humans. 
 The compact tension specimen must meet some dimensional requirements to 
have a valid test.  According to ASTM E 399 recommendations, the dimensions 
should meet the following: 
 
 
 The CT specimens were machined using the same proportions as those 
described by Norman, et al. (1996), with B equal to 0.5 mm and W being 
approximately 5 mm, and the crack length a is 2 mm long. 
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Figure 2.3.3-1: Schematic of the Compact Tension (CT) specimen. 
 Although fracture toughness testing for bone may not satisfy the reguirous 
requirements laid out above for plain strain fracture toughness, fracture toughness is 
still useful in comparisons within groups. 
2.3.4 Stress Analysis Calculations 
 
There are three modes of testing, therefore there are three stress intensity 
values that depend on the type of testing employed.  These three stress intensity 
values are denoted in the literature as Kk, where k is a I, II, or III depending on the 
mode of testing used.  
The stress intensity value, K, is the fracture toughness parameter of the 
stresses around the crack tip.  The testing used in this experiment was mode I and the 
mode I stress intensity factor can be calculated from equation 1. 



=
W
af
WB
P
K QIC    (1) 
Where a is the length of the chevron from the crack tip to a line connecting the two 
holes, W is the linear length from the holes to the end of the specimen past the tip, B 
 W
1.25 W
1.2 W
a
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is the thickness of the specimen, f(a/W) is a dimensionless geometric property called 
the shape factor.  The shape factor can be calculated using equation 2.   
5.45.35.25.15.0
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The load PQ is found from the analysis of the test results. The results are plotted on a 
graph of load versus displacement, as shown in figure 2.3.4-1.   
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Lo
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Figure 2.3.4-1: Fracture toughness test results plots with 5% secant line plotted. 
The slope is found for the elastic portion, linear portion, of the graph.  A 5% secant 
line is drawn from the linear portion of the graph, to insure that the plane strain 
condition is maintained.  After the line is drawn, the intersection between the line and 
Test Data
5% Secant Line 
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the test results is the P5 value, which if it meets the following conditions is used as PQ 
in the equation above.  PQ must meet the condition of: 
QPP 10.1max ≤  
This condition can be seen in figure 2.3.4-2, when the 5% secant line is plotted.   
 
Figure 2.3.4-2: Fracture toughness test result analysis, showing the three possible 
outcomes of the 5% secant line being plotted on the graph (Anderson, 1991). 
 
If P5 occurs after Pmax , as in Type III in figure 2.3.4-2, Pmax is used to satisfy the 
condition of stress at the initiation of the crack, and using this P5 would underestimate 
the fracture toughness of the material.   If the test data shows a pronounced spike, as 
in Type II in figure 2.3.4-2, and then a decrease before continued increase, the value 
as the top of this spike is used as the PQ value, since the equation is concerned with 
the initiation of the crack, which would has occurred around this point, and not at the 
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point found by Pmax or the 5% secant line.  If P5 occurs as shown in Type I in figure 
2.3.4-2, than this value is used as PQ 
Another property of fracture toughness testing that is analyzed is the 
compliance, which is the inverse of the slope of the linear portion of the stress versus 
displacement graph of the test values. 
 
2.4 Specimen Orientation 
 
 Bone properties are directional dependent, so the orientation must be given 
special consideration.  ASTM defines the crack direction as shown in figure 2.4-1. 
 
 
 
 
Figure 2.4-1: Crack direction definition for cylindrical geometries (ASTM, 1989; 
Anderson, 1991). 
 
Some literature values do not define the directions as shown in figure 2.4-1, so care 
must be used in deciphering the type of test used.  Using the above definition, the 
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long axis would correspond to the longitudinal direction or L in the above figure.  
Fracture toughness specimens in this study were from a C-L orientation. 
 Cracks in ungrooved specimens tend to propogate in the longitudinal direction 
reguarless of the loading direction (Behiri and Bonfield, 1989), which would imply 
that bone is less tough in this direction.  To overcome the tendency for the crack to 
propagate in the longitudinal direction, grooved speciemens were introduced to direct 
the crack.  Experiments using grooved bovine tensile speciemens showed that KIC 
was the greatest transverse to the bone’s long axis followed by cracks 15o to the long 
axis with KIC for the longitudinal (0o from the long axis) being the lowest (Behiri and 
Bonfield, 1989). 
2.5 Tibial Fracture Toughness Values from the Literature 
 
The fracture toughness of bone has been studied by several researchers (Table 2.4-1), 
but the particular effects of treatment on the fracture toughness are not known, which is the 
purpose of this study. 
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Table 2.4-1: Stress Concentration Factors for the Literature for the Tibia (Adapted from 
Yeni, 1998) 
Author(s) Species Experiment Measurement Direction Loading Rate
Bonfield & Datta 
(1974) Bovine Center Notched Shock Tube Kc=0.23 Longitudinal ~ 7 s^-1 
Bonfield & Datta 
(1976) Bovine Single-edge Notched Kc=2.2 - 4.6 Transverse 3e-3 s^-1 
Behiri & Bonfield 
(1980) Bovine CT Kc = 4.46 - 5.38 Longitudinal 
0.0102 - 1.02 
mm/min 
Behiri & Bonfield 
(1982) Bovine CT Kc = 3.3 - 5.7 Longitudinal  
Behiri & Bonfield 
(1984) Bovine CT Kc = 2.8 - 6.3 Longitudinal 
0.01 - 50 
mm/min 
Human CT Kc = 2.1 - 4.7 Longitudinal 0.504e-3 mm/min Bonfield et al. 
(1985) 
Canine CT Kc = 3.2 - 6.5 Longitudinal 0.0102 mm/min 
Moyle & Gavens 
(1986) Bovine Single-edge Notched Kc = 11.2 Transverse 0.45 mm/min
Behiri & Bonfield 
(1989) Bovine CT (grooved) Kc = 3.2 Longitudinal 
0.0198 
mm/min 
Norman et al 
(1991) Human CT Kc = 4.48 Longitudinal 0.5 mm/min
Norman et al 
(1991) Human 
CT (corrected for 7 mm 
thickness) Kc = 3.68 Longitudinal 0.5 mm/min
Norman et al 
(1992) Bovine CT Kc = 5.3 - 9.4 Longitudinal 0.5 mm/min
Norman et al 
(1992) Bovine CT (grooved) Kc = 5.2 - 9.3 Longitudinal 0.5 mm/min
Valishth et al 
(1994) Bovine CT Kc = 4 - 7.6 Longitudinal 0.5 mm/min
Valishth et al 
(1994) Human CT Kc = 1.6 - 2.5 Longitudinal 0.5 mm/min
Norman et al 
(1995) Bovine CT Kc = 4.68 - 6.73 Longitudinal 2.6 mm/min
Norman et al 
(1995b) Human CT Kc = 4.05 - 4.32 Longitudinal 2.6 mm/min
Feng & Salzmann 
(199) Bovine CT Kc = 2.55 Longitudinal 0.2 mm/min
Norman et al 
(1996) Human CT Kc = 2.12 Longitudinal 0.2 mm/min
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CHAPTER 3: FEMORAL NECK TESTING 
3.1 Introduction to Femoral Neck Testing 
 
 As it has been mentioned earlier, femoral neck fractures are a common type of 
osteoporotic fracture.  Femoral neck testing is a test of the femoral head and neck 
structure, namely the femoral neck’s ability carry load.  This testing was done to find 
the ultimate strength of the femoral neck structure, and to see if the treatment had an 
effect on the load carrying ability of the femoral neck, which would ultimately relate 
to the femoral neck’s ability to resist fracture. 
 The geometry of the femoral neck of rabbits differs from the human femoral 
neck that these test are often performed, but the rational of being able to test a 
structure is the same, even if the structure is different. 
3.2 Rational for Testing 
 
 The tests were performed to gain insight into structural changes of the bone 
and its ability to carry load, which gives another area to correlate the fracture 
toughness data.  The femur is a heavily loaded region and is commonly involved in 
osteoporotic fractures, and is second in prevalence after vertebral compression 
fractures. 
 The femoral neck is a common area for fracture in humans because of the 
relatively small size, low mass, and heavy loads received under normal activities.  
The rabbit femur is unique in the large femoral neck region that goes lower on the 
shaft relative to size than the human counterpart, which makes the fracture behavior 
unique.  The unique fracture properties do not make the femur untestable, since this 
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characteristic is shared by all of the test specimens, and a difference can be found 
between treatment groups. 
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CHAPTER 4 HISTOMORPHOMETRY OF BONE 
4.1 Introduction to Histomorphometry 
 
 Histomorphometry is the term used to describe the measurement and 
quantification of microscopic specimens.   
4.1.1 Example of use of the Lexicon 
 
The abbreviations are used in the order of the words in the measurement 
description, such as single pore area, which would be abbreviated as s.Po.Ar.  The use 
of abbreviations was standardized, but was not overly suggested by Parfitt (1987) 
with the purpose of standardizing abbreviations when used to report data.  The 
abbreviations will be used in this paper to report measurements, because of their 
compact size and the ease to which they lend themselves to the potential writing of 
data analysis computer programs for post processing of the data. 
4.1.2 Example of Measures 
 
 There are different types of histomorphometric measures.  These measures 
can be divided in a few categories namely: static and dynamic, and primary and 
secondary (calculated) measures. 
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Table 4.1.1: Abbreviations and Symbols of Terms Used in Bone Histomorphometry (Parfitt, 
1987) 
 
A 
Ab 
Ac 
Aj 
Ar  
a 
B 
BMU 
Ca 
Cd 
Cn 
Ct 
d 
E 
EX 
F 
Fb 
Fr 
f 
G 
H 
Hp 
Ht 
Hz 
I 
Ic 
Il 
In 
Ir 
i 
L 
Lc 
Le 
Lm 
Ln 
Lo 
l 
M 
Me 
Ml 
Apposition(al) 
Absolute 
Activation 
Adjusted 
Area (2D) 
Activ(e)(ity) 
Bone 
Basic Multicellular Unit 
Canal(icula)(r) 
Corrected 
Cancellous 
Cortical 
Double 
Ero(ded)(sion) 
External 
Formation 
Fibro(sis)(us) 
Front 
Frequency 
Grow(th)(ing) 
Haversian 
Hypertrophic 
Height 
Horizontal 
Interface (3D) 
Intercept 
Initial 
Internal 
Inter 
Intersection 
Label(led) 
Lacuna(r) 
Length 
Lamella(r) 
Line 
Longitudinal 
lag 
Mineral(iz)(ing)(ation) 
Medullary 
Modeling 
 m 
N 
n 
O 
Ob 
Oc 
On 
Ot 
P 
Pm 
Po 
Ps 
Pt 
Q 
R 
Rd 
Rf 
Rm 
Rs 
S 
Sa 
Se 
Sn 
St 
s 
Tb 
Th 
Tt 
t 
U 
V 
Vd 
Vk 
Vt 
W 
Wi 
Wo 
Z 
 
Maturation 
Number of profiles or structures 
Number of sampling units 
Osteoid 
Osteoblast(ic) 
Osteoclast(ic) 
Osteon(al) 
Osteocyt(e)(ic) 
Period 
Perimeter (2D) 
Por(e)(ous)(osity) 
Periost(eal)(eum) 
Point 
Quiescent 
Rate 
Radi(al)(us) 
Referen(ce)(t) 
Remodeling 
Resorption 
Surface (3D) 
Sample 
Section 
Spongiosa 
Structur(e)(al) 
Single 
Trabecula(r) 
Thickness (3D) 
Total 
Time 
Unit 
Volume (3D) 
Void 
Volkmanns 
Vertical 
Wall 
Width 
Woven 
Zone 
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4.3 Static Histomorphometry 
 Static histomorphometry is the microscopic measure of surfaces and 
structures.  The measures are called static, because the structures and surfaces of 
bone, are no longer living, embedded in plastic, and are unchanging.   
Most measures are in terms of percent of the total area, which is done for a 
few reasons.  Measures of length, when dealing with such small sizes, are difficult.  
The surfaces and areas of interest are irregular in shape, so the use of linear measures 
to then extrapolate an area is difficult.  Image analysis software that easily allows the 
measure of the percent of the total area occupied by a unique region. 
Total Area (TtAr) 
 The total area is exactly that, the total area of the image.  When a picture is 
analyzed, the measures are usually in terms of percentage of a larger area, and this is 
the most basic one. 
Medullary Area 
 The medullary area is the area enclosed by the cortical bone.  For illustrative 
purpose, a long bone (i.e. femur, or tibia) can be thought of as hollow pipes.  The 
medullary area would then be the area found from internal diameter (ID).  The 
medullary area is often thought of as a percentage of the total area from the equation: 
MeAr (%) = MeAr/TtAr 
Cortical Bone Area (CtAr) 
 The cortical bone area is defined as the area that is composed of cortical bone, 
and is usually expressed as a percentage of the total bone area by the equation. 
CtAr = TtAr – MeAr-Other Area 
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Other Area is all the area that may lie on the outside of the cortical bone that is not 
part of the medullary area, and is not bone area, such as any area in the field that lies 
outside of the cortex.   
The cortical bone area though is often reported as a percentage of the total 
area, from the equation: 
CtAr (%) = CtAr/TtAr = 1-MeAr/TtAr = 1 – MeAr (%) 
Osteon Area (OnAr) 
 The osteon area is expressed as the percentage of the total area that is 
composed of osteons, or more precisely the percentage of the bone area that is 
enclosed within cement lines, which are the boundaries of the osteon.  The area of 
each osteon is summed and then divided by the total cortical bone area (CtAr), or 
from the equation: 
OnAr = TOnAr/ CtAr 
Porosity (Po) 
 The porosity of the bone or the percentage of the total bone that is porous is 
found by finding the areas of the haversian, and volkmann canals, any other spaces 
that are present in the cortical bone, and the total area of the cortical bone.  The 
porosity (Po) can then be found by the equation: 
ArTt
ArVArCnVArCnHnPo
.
..Pr.... ++
=  
Osteon Number (OnN) 
 The osteon number is simply the number of osteons present in the bone 
specimen, which is measured by using analysis software to count the number of 
osteons identified by the user.  This parameter gives an idea as to the 
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resorption/formation activity present in the bone, but does not give areas of any sort.  
If two osteons and haversian canals are merged together, as shown in figure 4.3-1, 
they are counted as two osteons, because they are two independent osteons. 
 
Figure 4.3-1: Merged osteons (Wang, 1995). 
If two osteons are merged by a Volkmann’s canal, these are also counted as two, 
because they are independent osteons. 
 
Figure 4.3-2: Osteons connected by a Volkmann’s canal (Wang, 1995). 
If the Haversian canals are separate, but the osteons are merged together, each osteon 
is counted, because each is still an independent system. 
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Figure 4.3-3: Merged osteons with independent Haversian canals (Wang, 1995). 
When images are made, some osteons may only be partially in the field as shown in 
figure 4.3-4.  The partial osteons are counted as well. 
 
Figure 4.3-4: Osteon fragment cut by edge of the field (Wang, 1995). 
If an osteon fragment does not have a clear haversian canal (figure 4.3-5), but does 
have a clear cement line, the fragment is also counted, because it has important 
mechanical properties similar to those of osteons with Haversian canals. 
 
Figure 4.3-5: Osteon fragment with a clear cement line (Wang, 1995). 
Occassionally an osteon will appear to have a double cement line, which could be 
caused by the specimen being sectioned oblique to the face or to a small remodeling 
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event.  The osteon, similar to the schematic in figure 4.3-6, is counted as one, and the 
outer cement line is used for measurement purposes. 
 
Figure 4.3-6: Osteon, which appears to have two cement lines (Wang, 1995). 
Osteon Density (OnD) 
 Osteon density is an index of the number of osteons per unit area, which can 
be found from the equation. 
OnD = OnN/CtAr 
Osteoid Area (OAr) 
 The osteoid area is the area of the bone occupied by osteoids, but this quantity 
like most bone quantities is given as a percentage of the cortical bone area from the 
equation. 
OAr = OAr/CtAr 
4.4 Compositional Analysis (R Cain et al, 2003) 
 
The mineral and organic content of bone can be found from a drying 
procedure as follows: 
1. The dimensions of the specimen were measured using calipers, and the 
volume (V) of the cylinder was calculated. 
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2. The specimens were hydrated overnight in water, lightly blotted dry, 
and then the wet weight (WW) was found. 
3. The specimen was then defatted by soaking in acetone in a vacuum 
oven (20 psi; 60 oC) for 24 hours. 
4. The specimen was brought back to room temparature in a dessicator (1 
hour).  The specimen was then weighed.  This was repeated until a 
constant mass was found, which is the dry weight (DW). 
5. The specimens were then placed in a crucible in a muffle oven at 600 
oC for 24 hours.  The specimen’s ash weight (AW) was then found. 
6. The following parameters were then calculated: 
Weight Density = WW/V 
Dry Density = DW/V 
%Mineral, %Min = AW/DW * 100 
%Organic (dry) = (DW – AW)/DW *100 
%ASH = AW/DW * 100 
%Organic (wet) = (DW – AW)/WW *100 
% Water = (WW-DW)/WW * 100 
The %Ash can be thought of as the apparent mineral content, and the 
%Mineral is the material mineral content and is independent of porosity.  The 
%Organic (dry) is the organic content and is independent of porosity, and the 
%Organic (wet) is the apparent organic content of the bone. 
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CHAPTER 5 ANIMAL CARE AND EXPERIMENTAL PROCEDURE 
 
5.1 Introduction 
 
The experiment used a total of twenty-eight New Zealand White (NZW) 
rabbits (Covance, Denver, PA), which were divided into three trial groups and four 
treatment groups. 
Group I (N = 6) 
Group I consisted of eight rabbits.  Four of these rabbits were ovarectomized 
and four of them were sexually normal.  The purpose of this group was to illustrate 
the difference between the overectomized and normal groups, and add validity to the 
rabbit Ovx model. 
Group II (N = 8) 
Group II consisted of eight rabbits, all of which had received ovarectomies.  
Four of the animals received risidronate injections of 5 µg/ml/kg three days per week 
(M, W, and F), meaning animals in this group that received Residronate (Actonel, 
Proctor and Gamble) received an injection of a solution of a concentration of 5 µg/ml 
and then given a dose of one ml per kg of body weight.  The remaining four rabbits 
received saline injections equal to 1 ml/kg. 
Group III (N = 16) 
This group consisted of all four treatment methods (Normal, Ovx-NaCl, Ovx-
Ris, Ovx), as described previously with four animals per treatment method. 
A more visually pleasing representation of the division of specimens can be 
seen in table 5.1-1. 
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Table 5.1-1: Animal Treatment and Group Distribution Table 
 
Normal (No Injection) 
Group I: n = 5 
Group III: n = 4 
Ovx (No Injection) 
Group I: n = 4 
Group III: n = 4 
Ovx (Residronate Injection) 
Group II: n = 4 
Group III: n = 4 
Ovx (Saline Injection) 
Group II: n = 4 
Group III: n = 4 
 
 
5.2: Animal Care Introduction 
 
 Animals deserve a level of respect and consideration when an experiment is 
designed.  There are many moral and legal issues that must be addressed before the 
use of animals should be considered. 
 Animals should not be used in experiments unless the data is simply 
unavailable from any other model.  If the data can also be derived by a computer 
model, even if the accuracy is lower than an in vivo model, it should be strongly 
considered. 
 From a legal point-of-view, the use of animals is strongly regulated by the 
United States Government under the authority of the Department of Human Services.  
 All of the animals in the study were housed by the West Virginia University 
Office of Laboratory Animal Research at the Robert C. Byrd Health Sciences Center 
Morgantown, WV.  The animal quarters officials took care of feeding, watering, and 
cleaning duties necessitated by the use of animals. 
 The experimental procedure received Animal Care and Use Committee 
(ACUC) approval (# 01-1102). 
  - 46 - 
 
5.3: Animal Injection Procedure 
 
 All injections were given subcutaneous on the dorsal side of the animal.  The 
animal was placed on a flat surface outside of its cage, and the skin of the posterior 
dorsal region was pinched up.  The needle was then inserted into the skin horizontally 
along the length of the pinch.  The plunger was then slowly pressed forward, to allow 
for the maximum comfort of the animal, since a relatively large volume of fluid is 
being introduced to the animal.  The area was then examined by lightly rubbing the 
hand over the dorsal area in a petting motion.  The petting has a two pronged purpose:  
it allows for the checking of dosing, since if the injection is not fully successful, the 
liquid will be stuck in the fur and will not be readily visible, and the stroking of the 
animal helps to comfort and sooth the animal, that is stressed by the injection 
procedure. 
5.4: Animal Sacrifice Procedure 
 
 The animals were brought from the animal housing area to the operating 
room, in which the dissections were to take place.  The animal is anesthetized using 
an injection of Ketamine (Ketajet, 100mg/ml, Phoenix Scientific, St. Lois, MO) and 
Xylene (Xylajet, 20 mg/ml, Phoenix Scientific, St. Lois, MO) in a 30 ml to 10 ml 
mixture.  Once the animal is asleep, an injection 30 ml of Sleep Away (Fort Dodge 
Laboratories, Fort Dodge, IA) is injected directly into the cardiac muscle, which leads 
to almost instantaneous cardiac arrest. 
 
5.5: Animal Dissection 
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 Once the animal is confirmed dead, the hind limbs are dissected and the 
femurs and tibias are removed and cleaned.  The bones were wrapped in saline 
soaked gauze and placed in labeled bags. The specimens were then placed in a freezer 
(-20 oC), until the specimens were used in mechanical testing. 
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CHAPTER 6: SPECIMEN PREPARATION, MACHINING, AND ANALYSIS 
6.1 Bone Selection and Bone Availability 
 The tibia was selected for the preparation of the fracture toughness specimens, 
because of the relatively flat aspects of the bone on the proximal end, which allows 
for the machining of the compact fracture toughness specimens. 
 
6.2 Specimen Preparation and Storage 
 When machining was going to be performed on the bones, only the number 
expected to be machined that day were removed from the freezer in the morning to 
defrost at room temperature.  Hydration was maintained as well as possible during the 
machining process using normal saline to avoid drying out of the specimens. 
 After the machining process, the specimens were wrapped in saline soaked 
gauze and then placed in a labeled plastic bag; after which, the bones were placed in 
the refrigerator (4 oC) for no more than a few days until testing took place. 
 Before mechanical tests were performed, the bone specimens were removed 
from the refrigerator and allowed to return to room temperature, before testing was to 
begin.  Hydration was maintained throughout the testing process using normal saline. 
 
6.3 Fracture Toughness Machining 
 All specimens were removed from a flat lateral aspect of the proximal tibia 
adjacent to the fibula as shown in figure 6.3-2.  This area provided the flattest and 
thickest area of cortical bone from which to extract a fracture toughness specimen. 
The proximal end was removed by cutting it off perpendicular to the axis of 
the bone using a band saw at a location low enough on the shaft of the bone, such that 
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there was sufficient cortical bone for the machining of the specimens. Using a 
jeweler’s saw with a fine cutting blade, a slab was then removed along the selected 
flat aspect down the shaft of the bone, care was taken to ensure that a minimum 
amount of the other faces were removed, while still allowing the removal of the entire 
aspect down to approximately the midpoint of the shaft.   
The slab once removed was ground flat using wet 180# sandpaper, and then 
placed on a specially designed fixture designed by Vincent Kish and myself (figure 
6.3.1) and secured using the set screws.   
 
 
 
 
 
 
 
 
Figure 6.3.1: Machining Fixture for Milling and Drilling Processes 
17.1 mm
6.8 mm
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Figure 6.3-2: Fracture Toughness Specimen Location and Dimensions (Adapted from 
Wingerd, 1985 with CT specimen added) 
 
 The slab once secure in the fixture (Figure 5.3-1) was placed in the clamp in 
the vertical milling machine, and the center portion between the two clamps was 
milled to the desired thickness of 0.5 mm using a 3/16” milling bit running at 2300 
RPM. 
 Once the center portion was milled to the correct thickness (0.5 mm), the 
holes for the fracture toughness specimen were drilled by putting a 1 mm diameter bit 
into the head of the milling machine and using as a press at 270 RPM.   The hole 
placement was found by using a Mill Mate (Bridgeport, Bridgeport, CT) digital 
device that is connected to the bed of the mill/press and reads distance change on the 
horizontal plane. 
 W
1.25 W 
1.2 W 
a 
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 Once the holes were drilled into the specimen, it was removed from the 
fixture, and the measurements for the dimensions were made using the center of the 
holes as a reference point. 
 Once the measurements were transferred in pencil to the specimen, it was 
removed and cut to the proper length using a Buhler Low Speed Saw. 
 Once the specimen was the proper length, the crack was cut into the specimen 
on the Low Speed Saw (Buehler, Evanston, IL) using a blade of 10.2 cm diameter and 
a thickness of 0.3 mm. 
 Prior to testing, the precrack was made at the end of the crack using a new flat 
razor blade. 
 
Figure 6.3-3: Making of the precrack (Yeni, 1998). 
6.4 Histomorphometric Preparation 
 Complete cross sections were cut from the tibial shaft below the area used for 
the fracture toughness machining.  A bulk section was cut from the middle of the 
shaft.  The bulk section was embedded in plastic.  After the embedding process, at 
least two 80 mm sections were cut using a diamond wire saw (Delaware Diamond 
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Knives, Wilmington, DE).  At least one section was stained using H&E (Appendix 
A); the section after staining was mounted on a microscope slide with Permount 
(Fisher Scientific, Fairlawn, NJ) and a cover slip was applied.  At least one other 
section was mounted on a slide unstained using Fleoromount-G (Southern 
Biotechnology Associates Inc., Birmingham, AL) for dynamic histomorphometry. 
6.5 Femoral Neck Fracture Testing 
 
 The femoral neck was tested by cutting the femur perpendicular to the axis at 
the mid-shaft, taking care to insure that it was below the obvious neck structure.  The 
bones were then “potted” or fixed in a metal tube using Duz-All Self Cure Acrylic 
Dental Cement from Coralite Dental Products (Skokie, IL).  The structure of the 
femoral neck was then tested on the MTS (MTS Corp., Minneapolis, MN).   
 
 
 
 
 
 
 
 
 
Figure 6.5-1: Femoral neck testing configuration with the arrow indicating the load. 
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6.6 Bone Mineral Density Testing 
 
 The bone mineral density of the femurs for group II were tested at the Ohio 
State Musculoskeletal Research Center by Dr. John Landell.  The bones were shipped 
to the OSU lab by FedEx in a Styrofoam box with dry ice.  The bones upon receipt at 
OSU were kept frozen and then tested using DXA.  After the analysis the bones were 
shipped back to Morgantown, WV, using the same box with dry ice. 
 
6.7 Histomorphometric Analysis 
 
 Four fields were selected at random and an image was captured using the 20x 
objective on the microscope (Olympus BH-2, Japan).  The images were then analyzed 
using Scion Image version Beta 4.02 (Scion Corporation) and the results were 
exported as a text file.  The text file was then opened in Microsoft Excel version 
9.0.2720 for analysis.  After the analysis, statistical analysis was performed using 
JMP (version 3.2.1, SAS Institute, Inc). 
 
6.8 Statistical Methods 
 
 Statistical comparisons between groups and line fitting for the data was 
performed in JMP (version 3.2.1, SAS Institute, Inc).  Significance was tested using 
ANOVA, student t-test, and Tukey-Kramer HSD.  The confidence interval was set at 
95% (p<0.05). 
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CHAPTER 7: RESULTS 
7.1 Introduction 
 
 The data in this investigation was for determining the bone quality of bone, 
and the effects of estrogen deficiency and bisphosphonate treatment on the quality of 
bone.  To get a clearer picture as to the effects of the drug treatment and estrogen 
deficiency on the mechanical properties a variety of tests were employed.  The most 
important for our study was fracture toughness, and the other tests and measures were 
done to explain the difference or lack of differences found from this test. 
7.2 Fracture Toughness Results (Stress Intensity Factor) 
 
 Fracture toughness testing was performed for all three groups.  The stress 
intensity factors were calculated as described earlier, and the results in each group 
were compared, within the same experimental group and all groups. 
Group I: 
 
 The fracture toughness of Group I was performed using a different machining 
technique than that employed in groups II and III.  During this test many of the 
specimens broke during the machining process, particularly the Ovx bones, which 
were seemingly too brittle to go through the machining process without breakage.  
The difference between the treatment groups was significant, but the Ovx only had 
one specimen in the test.  The results for the group can be seen in table 7.2-1 and 
figure 7.2-1. 
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Table 7.2-1: Fracture Toughness Test Data for Group I. 
 
Specimen 
W 
(mm) a (mm) Fc (N) B (mm) a/W f(a/W)
Kc 
(N/mm^3/2) Treatment
977 6.80 2.40 5.76 0.60 0.35 6.59 24.27 Ovx 
         
981a 6.33 2.00 12.84 0.81 0.32 6.08 38.32 Norm 
981b 6.50 2.20 11.98 0.80 0.34 6.38 37.47 Norm 
982 5.58 2.40 9.25 0.63 0.43 7.96 49.47 Norm 
983 5.80 2.50 4.57 0.50 0.43 7.98 30.32 Norm 
Normal Avg. 6.05 2.28 9.66 0.69 0.38 7.10 38.90  
Normal SD 0.43 0.22 3.72 0.15 0.06 1.01 7.91  
 
Figure 7.2-1: Stress intensity factor results for Group I (The average value for 
Normal is 38.9±7.91 and the only value for Ovx was 24.27). 
 
Group II: 
 
In Group II, the stress intensity factors were not significantly different 
between Ovx and Ovx-Ris groups, which can be see in table 7.2-2 and figure 7.2-2. 
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Table 7.2-2: Fracture toughness test values for Group II 
 
Treatment Number Mass (kg) Fc (N)
a 
(mm)
W 
(mm) T (mm) a/W f(a/W) 
Kc 
(N/mm^3/2)
NaCl 20.00 4.40 11.68 1.37 6.85 0.77 0.20 5.23 30.30 
NaCl 22.00 5.10 14.34 1.24 6.07 0.61 0.20 5.24 49.99 
NaCl 23.00 4.80 13.67 1.21 6.84 0.53 0.18 5.21 51.34 
 Average 4.77 13.23 1.27 6.59 0.64 0.19 5.23 43.88 
 SD 0.35 1.39 0.09 0.45 0.12 0.01 0.02 11.78 
 
Ris 21.00 4.80 18.44 1.18 7.06 0.53 0.17 5.21 68.22 
Ris 24.00 6.00 8.80 1.40 6.58 0.49 0.21 5.26 36.83 
Ris 25.00 4.30 10.92 1.18 6.71 0.33 0.18 5.21 66.51 
Ris 26.00 3.50 12.15 1.44 6.49 0.56 0.22 5.30 45.10 
Average 4.65 12.58 1.30 6.71 0.48 0.19 5.24 54.16  
SD 1.05 4.15 0.14 0.25 0.10 0.03 0.04 15.63 
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Figure 7.2-2: Stress intensity factor results for Group II (The average values are 
43.88±11.78 N/mm^1.5 for Ovx-NaCl and 54.16±15.63 N/mm^1.5 for the Ovx-Ris 
group) 
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The stress intensity factors for all of the treatment in Group III were 
calculated, but none of the groups was significantly different, as can be seen in figure 
7.2-3 and table 7.2-3. 
Table 7.2-3: Fracture toughness test data for Group III 
 
Treatment Number Mass (kg) Fc (N) a (mm) W (mm) B (mm) a/W f(a/W) 
Kc 
(N/mm^3/2)
Normal 127 4.91 13.2085 1.28 4.74 0.55 0.27 5.60 61.75 
Normal 128 2.90 7.0593 0.86 4.64 0.63 0.19 5.21 27.10 
Normal 129 5.02 9.9543 1.03 3.93 0.66 0.26 5.53 42.10 
Normal 130 4.85  1.30 3.60 0.52 0.36 6.71 0.00 
Normal Average 4.28 10.07 1.06 4.44 0.61 0.24 5.45 43.65 
Norma SD 1.19 3.08 0.21 0.44 0.06 0.05 0.21 17.38 
          
NaCl 138 5.67 13.2714 1.40 4.67 0.56 0.30 5.89 64.60 
NaCl 139 4.71 12.3344 1.17 4.32 0.79 0.27 5.61 42.10 
NaCl 141 4.55 6.9785 1.38 4.47 0.64 0.31 5.99 30.91 
NaCl 142 4.31 16.0137 1.3 5.6 0.88 0.23 5.34 41.07 
NaCl Average 4.81 12.15 1.31 4.77 0.72 0.28 5.71 44.67 
NaCl SD 0.60 3.78 0.10 0.57 0.14 0.03 0.29 14.21 
          
Ris 131 4.61 12.0799 1.15 4.62 0.5 0.25 5.44 61.13 
Ris 132 4.9 15.7682 1.06 4.9 0.67 0.22 5.27 56.08 
Ris 133 5.45 9.7627 1.06 4.11 0.52 0.26 5.50 50.95 
Ris 136 4.76 17.8788 1.13 4.75 0.57 0.24 5.37 77.31 
Ris Average 4.93 13.87 1.10 4.60 0.57 0.24 5.40 61.37 
Ris SD 0.37 3.64 0.05 0.34 0.08 0.02 0.10 11.41 
          
Ovx 134 4.71 14.2085 1.02 4.94 0.66 0.21 5.24 50.80 
Ovx 135 4.83 11.7027 1.29 4.73 0.57 0.27 5.62 53.07 
Ovx 137 4.6 13.0379 1.2 4.5 0.67 0.27 5.57 51.10 
Ovx 140 4.88 16.5915 1.46 4.64 0.68 0.31 6.06 68.69 
Ovx Average 4.76 13.89 1.24 4.70 0.65 0.27 5.63 55.91 
Ovx SD 0.126 2.07 0.18 0.184 0.051 0.045 0.34 8.58 
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Figure 7.2-3: Stress intensity factor results for Group III (The  average values were 
43.65 ± 17.38 N/mm^1.5 for Normal, 44.67 ± 14.21 N/mm^1.5 for Ovx-NaCl, 61.37 
± 11.41 N/mm^1.5 for Ovx-Ris , and 55.91 ± 8.58 N/mm^1.5 for Ovx.) 
 
All Groups 
 
 When all of the stress intensity factors from all three groups were put together, 
the Ovx-Ris group was found to be significantly different the Normal group, but there 
was no other significant difference, as shown in figure 7.2-4, using data from tables 
7.2-1, 7.2-2, and 7.2-3. 
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Figure 7.2-4: Stress intensity factor results for Groups I, II, and III (The  average 
values were 40.93 ± 11.77 N/mm^1.5 for Normal, 57.71 ± 22.36 N/mm^1.5 for Ovx-
NaCl, 76.23 ± 26.83 N/mm^1.5 for Ovx-Ris , and 49.58 ± 15.98 N/mm^1.5 for Ovx.) 
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7.3 Femoral Neck Testing 
 
 Femoral neck testing was performed for all three groups. 
 
Group I: 
 
 In Group I, the Ovx group had a significantly higher amount of displacement 
from start of loading to fracture (figure 7.3-1 and table 7.3-1), but the load at fracture 
was not significantly different (figure 7.3-2 and table 7.3-1). 
Table 7.3-1: Femoral Neck Test Results for Group I 
 
Specimen Load (N) Displacement (mm) Treatment
982 -1339.68 -2.4173 Normal 
983 -858.275 -2.4785 Normal 
Average -1098.98 -2.4479  
SD 340.4025 0.043275  
977 -1183.48 -3.2246 Ovx 
979 -1037.7 -3.4234 Ovx 
Average -1110.59 -3.324  
SD 103.0761 0.140573  
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Figure 7.3-1: Comparison of Displacement at Fracture for Group I (Averages are for Normal 
-2.45 ± 0.04 mm and for Ovx -3.32 ± 0.14 mm).  
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Figure 7.3-2: Graph of Force at Fracture for Group I (Averages are for 
Normal –1099 ± 340 N and for Ovx –1111 ± 103 N). 
 Group II: 
 
 The displacement from beginning of load until fracture (figure 7.3-3 and table 
7.3-2) and the ultimate load (figure 7.3-4 and table 7.3-2) were not significantly 
different for the Ovx-NaCl and Ovx-Ris groups. 
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Table 7.3-2: Femoral Neck Test Results for Group II 
 
Specimen 
Force 
(N) 
Displacement 
(mm) Treatment 
19 -1288.24 -2.2057 NaCl 
20 -932.227 -2.1805 NaCl 
22 -1063.78 -2.7091 NaCl 
23 -1483.79 -2.4239 NaCl 
Average -1192.01 -2.3798  
SD 243.8075 0.245230912  
    
21 -1655.16 -3.5199 Ris 
24 -1176.6 -1.9057 Ris 
25 -949.53 -1.7817 Ris 
26 -718.903 -1.7472 Ris 
27 -1200.78 -2.3099 Ris 
Average -1140.19 -2.25288  
SD 347.8593 0.742773143  
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Figure 7.3-3: Femoral Head Displacement at Fracture for Group II (The average values were 
–2.38 ± 0.25 mm for Ovx-NaCl and –2.25 ± 0.74 mm.) 
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Figure 7.3-4: Femoral Head Force at Fracture for Group II (The average values were –
1192.01 ± 243.8 N for Ovx-NaCl and –1140 ± 347.9 N.) 
Group III: 
 
 The Ovx group had no significant differences in load (figure 7.3-5) or 
displacement (figure 7.3-6), this is also shown in table 7.3-3. 
O
vx
-N
aC
L 
O
vx
 - 
R
is
 
  - 64 - 
Table 7.3-3: Femoral neck test data for Group III 
 
Specimen Load (N) Displacement (mm) Treatment
127 1082.5 -2.89 Normal 
128 792.9 -4.09 Normal 
129 1345.83 -3.01 Normal 
130 942.7 -2.84 Normal 
Average 1041.0 -3.21  
SD 235.2 0.59  
    
131 1080.132 -3.24 Ris 
132 1116.16 -1.59 Ris 
133 1262.88 -2.72 Ris 
136 890.5103 -3.27 Ris 
Average 1087.421 -2.71  
SD 153.2304 0.78  
    
134 1084.635 -3.23 Ovx 
135 1638.568 -3.04 Ovx 
137 1289.901 -2.48 Ovx 
140 1120.427 -3.07 Ovx 
Average 1283.383 -2.95  
SD 253.1495 0.33  
    
138 1214.3 -2.46 NaCl 
139 1030.8 -2.59 NaCl 
141 937. 7 -3.14 NaCl 
142 1155.5 -3.12 NaCl 
Average 1084. 6 -2.83  
SD 124. 3 0.36  
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Figure 7.3-5: Load at Fracture of Femoral Neck for Group III (The average values 
were 1041.0 ± 235.2 N for Normal, 1283.4 ± 253.1 N for Ovx, 1084.6 ± 124.3 N 
Ovx-NaCl, and 1087.4 ± 153.2 N for Ovx-Ris.) 
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Figure 7.3-6: Femoral head displacement at fracture for Group III (The average 
values were –3.21 ± 0.59 mm for Normal, -2.95 ± 0.33 mm for Ovx, -2.83 ± 0.36 mm 
Ovx-NaCl, and –2.71 ± 0.78 mm for Ovx-Ris.) 
All Three Test Groups: 
 
 Data from all three test groups were compiled (tables 7.3-1, 7.3-2, and 7.3-3), 
and the results were compared, but there were no significant differences, as shown in 
figures 7.3-7 and 7.3-8. 
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Figure 7.3-7: Femoral neck ultimate strength for all three groups (The average values 
were 1060 ± 239.3 N for Normal, 1225.8 ± 220.3 N for Ovx, 1138.3 ± 188.1 N for 
Ovx-NaCl, and 1116.7 ± 264.7 N for Ovx-Ris.) 
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Figure 7.3-8: Femoral head displacement at time of fracture for all three groups (The 
average values were –2.96 ± 0.60 mm for Normal, -3.08 ± 0.32 mm for Ovx, -2.60 ± 
0.37 mm for Ovx-NaCl, and –2.45 ± 0.75 N for Ovx-Ris.) 
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7.4 Histomorphometric Results 
 
 The porosity was measured for Groups I and II, but there was no significant 
difference between treatment groups as shown in figures 7.4-1 and 7.4-2. 
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Figure 7.4-1: Porosity Percentage (Po) for Group I (The average values were 1.86 ± 0.74 for 
Normal, and 2.10 ± 1.07 for Ovx.) 
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Figure 7.4-2: Porosity Percentage (Po) for Group II (The average values were 2.86 ± 0.64 
for Ovx-NaCl, and 2.88 ± 0.82 for Ovx-Ris.) 
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7.5 DEXA Scan Results 
 
Table 7.5-1: DEXA Scan results from OSU and Analysis  
  Total Proximal 1/3   
Number Weight BMD BMC Area BMD BMC Area Treatment
  kg g/cm2 g cm2 g/cm2 g cm2   
19 4.9 0.458 5.694 12.443 0.381 1.974 5.185 NaCl 
20 4.4 0.427 5.257 12.307 0.358 1.882 5.251 NaCl 
22 5.1 0.382 4.269 11.186 0.321 1.473 4.593 NaCl 
23 4.8 0.469 5.046 10.751 0.405 1.768 4.37 NaCl 
Avg 4.8 0.434 5.0665 11.67175 0.36625 1.77425 4.84975   
Avg/kg  0.090417 1.055521 2.431615 0.076302 0.369635 1.010365   
                  
21 4.8 0.46 5.045 10.975 0.389 1.744 4.484 Ris 
24 6 0.439 5.161 11.762 0.37 1.813 4.905 Ris 
25 4.3 0.364 0.3766 10.348 0.284 1.248 4.395 Ris 
26 3.5 0.438 4.816 10.986 0.369 1.634 4.42 Ris 
27 3.7 0.371 4.213 11.347 0.319 1.509 4.738 Ris 
Avg 4.46 0.4144 3.92232 11.0836 0.3462 1.5896 4.5884   
Avg/kg   0.092915 0.879444 2.485112 0.077623 0.356413 1.028789  
                 
Difference 0.34 0.0196 1.14418 0.58815 0.02005 0.18465 0.26135  
(NaCl-Ris) Normalized -0.0025 0.176077 -0.0535 -0.00132 0.013223 -0.01842  
                 
%Diff 7.62331839 4.72973 29.171 5.306489 5.79145 11.61613 5.695885  
((NaCl-
Ris)/Ris*100) Normalized -2.68863 20.02139 -2.15272 -1.70211 3.709987 -1.79091  
 
The BMD of the Ris group is lower than that of the Saline control group, but 
when it is normalized on a per kg of body weight basis, the BMD of the Ris 
specimens are 2.7% greater than the saline control rabbits.  The BMD for the 
proximal third of the bone is greater in the Ris group, but only by 1.8% (normalized 
for body weight).  There were no significant differences between treatment groups 
regardless of parameter.  The DEXA results when plotted against body mass shows a 
slight trend, as shown in figure 7.5-1 
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Figure 7.5-1: DEXA scan results versus body mass. 
7.6 Weight Measurements 
 
 The weights of the animals were monitored in the injection groups because the 
dose volume was determined by the weight of the animal.  The weights of the other 
two treatment groups were monitored for comparison purposes. 
 The average weight at dissection was not significantly different between any 
of the groups.  The change in weight from the first day of the 140 day treatment until 
sacrifice was not significantly different.  The percent change from the beginning 
weight was, also, not significantly different for the Normal group compared to all of 
the Ovx groups, and there is no significant difference for the percent change of any of 
the Ovx groups, but there is the beginnings of a trend towards an increased 
percentage change in mass for the Ovx groups.  The relationships in mass can be seen 
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in figure 7.6-1 and table 7.6-1, Group I was not included, because weekly mass data 
is not available for this group. 
Table 7.6-1: Mass Results for Groups II and III 
 
Specimen Treatment Mass (kg) Change (kg) %Change 
127 Normal 4.10 0.81 19.76 
128 Normal 3.00 -0.10 -3.33 
129 Normal 4.00 1.02 25.50 
130 Normal 4.50 0.35 7.78 
 Average 3.90 0.52 12.43 
 SD 0.64 0.50 12.84 
     
134 Ovx 3.70 1.01 27.30 
135 Ovx 4.00 0.83 20.75 
137 Ovx 3.80 0.80 21.05 
140 Ovx 4.10 0.78 19.02 
 Average 3.90 0.86 22.03 
 SD 0.18 0.11 3.62 
     
19 NaCl 4.60 0.30 6.52 
20 NaCl 3.60 0.80 22.22 
22 NaCl 3.90 1.20 30.77 
23 NaCl 4.10 0.70 17.07 
138 NaCl 4.20 1.47 35.00 
139 NaCl 3.97 0.74 18.64 
141 NaCl 4.08 0.47 11.52 
142 NaCl 3.79 0.52 13.72 
 Average 4.03 0.78 19.43 
 SD 0.30 0.39 9.61 
     
21 Ris 4.20 0.60 14.29 
24 Ris 4.70 1.30 27.66 
25 Ris 3.80 0.50 13.16 
26 Ris 3.50 0.00 0.00 
27 Ris 3.50 0.20 5.71 
131 Ris 3.93 0.68 17.30 
132 Ris 3.88 1.02 26.29 
133 Ris 4.35 1.15 26.44 
136 Ris 3.64 1.12 30.77 
 Average 3.94 0.73 17.96 
 SD 0.41 0.45 10.66 
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Figure 7.6-1: Mass Results for Groups II and III 
 
7.7 Comparison of Results 
 
 The compliance is the inverse of the slope of the linear portion of the fracture 
toughness data, as shown previously.  A lower compliance value implies a stiffer 
material.  When the compliance is plotted versus the body mass, a relationship 
becomes evident as seen in figures 7.7-1 and 7.7-2. 
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Figure 7.7-1: Compliance versus body mass for Group III, shown with a second degree 
polynomial fit. 
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Figure 7.7-2: Compliance versus body mass data for Group III, with a linear trend line 
added. 
 To better understand the mechanisms of bone fragility in the estrogen 
deficient rabbit, relationships were investigated between various experimental 
measures.  No significant relationships were found, other than the compliance versus 
mass as shown in figures 7.7-1 and 7.7-2, but some graphs of interest are: 
• Load versus Mass for Groups II and III (Figure 7.7-3) 
• Femoral Head Displacement versus Body Mass for Groups II and III (Figure 
7.7-4) 
• Femoral Head Displacement versus Body Mass for Group III (Figure 7.7-5) 
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• BMD and BMC versus Body Mass (Figure 7.7-6) 
• Stress Intensity Factor versus Po for Group I (Figure 7.7-7) 
• Stress Intensity Factor versus Po for Group II (Figure 7.7-8) 
• Po versus Body Mass for Group II and III (Figure 7.7-9). 
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Figure 7.7-3:  Load versus mass for Groups II and III with linear fit. 
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Figure 7.7-4:  Femoral head displacement data for Groups II and III versus body mass. 
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Figure 7.7-5:  Displacement of the femoral head at fracture of Group III versus body mass 
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Figure 7.7-6: Plot of BMD and BMC versus body mass for Group II. 
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Figure 7.7-7: Stress Intensity Factor versus %Po for Group I. 
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Figure 7.7-8: The stress intensity factor versus the %Po for Group II. 
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Figure 7.7-9: Relationship of %Po versus body mass for Group II. 
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7.8 Torsion Testing Data (Cain, R, et al, 2003) 
 
 Another research project was being performed, using one of the tibias from 
Group III, by R Cain, et al.  This project was to investigate the bone composition, and 
torsional values for the estrogen deficient rabbit.  The results, although not 
significant, show the relationship of body mass to torque and angle of fracture in 
figure 7.8-1. 
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Figure 7.8-1: Torsional test data versus body mass for Group III.
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CHAPTER 8: DISCUSSION 
8.1 Discussion Fracture Toughness Data 
 
The data shows a trend that the Risedronate treatment increases fracture 
toughness of the bones, and this is also shown microscopically by the 
histomorphometric measures, but the model does not have enough numbers to prove 
statistical significance.  The compliance data implies that there is a strong correlation 
between body mass and bone properties, as can be seen in the figures 7.7-1, and 7.7-
2.  Hui et al. (2002) showed that decrease in bone mineral density can be offset by 
increases in body mass.  Bauer et al (1993), Shiraki et al (1991), Russel-Aulet et al 
(1993), Klementti et al (1997), Reid et al (1995), and Felson et al (1993) have all 
shown that bone mass is greatly effected by body mass.  The increase in body mass of 
the estrogen deficient rabbits could be a reason for the lack of difference in the 
experimental groups. 
Although Mashiba et al (2001) found a increase in bone mass and strength in 
rabbits after only one remodeling cycle (70 days), and Hirano et al showed favorable 
effects in rabbits after 140 days (1999) and after five months (2000), these results 
may not apply to our study, because they used an anabolic agent and an intact rabbit 
model.  Lugero, et al (2000) using an overectomized rabbit model found no 
significant difference in BMD in the rabbit tibia after 4 months, and believe this 
maybe from the particular R/F balance dynamic of the rabbit and the need for longer 
periods of time for the difference to manifest.  A guinea pig take approximately 6 
months for a BMD difference to be found.  Cao, et al (2000) found no significant 
diffence in cortical BMD after 4 and 12 weeks, but found a significant difference in 
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trabecular bone mass.  This experiment also found no significant difference in BMD 
of the femur for Group II, and this lack of change BMD could be a reason for the lack 
of difference in the fracture toughness values between groups. 
Fracture toughness, as found by Yeni and others, is dependent on many 
different factures and the exact mechanism for failure and the primary cause is still 
not known.  More study is necessary to find the mechanism of change in fracture 
resistance. 
8.2 Discussion of Histomorphometry Data 
 
 The bone specimens from the estrogen deficient animals would be expected to 
be more porous than those from the normal control specimens.  The increased 
porosity would then translate to decreased fracture toughness.  The results of our 
testing do not show this.  The lack of the hypothesized results could be from a lack of 
sufficient time for the increased level of resorption to outpace formation sufficiently 
for a greater amount of porosity than the normal control.   
 
8.3 Discussion of Femoral Neck Data 
 
 The femoral neck data showed a decrease in stiffness, but not a decrease in 
ultimate strength, since the ultimate load at fracture was not significantly different, 
but the displacement of the femoral head was significantly larger for the Ovx control 
groups, when compared to Normal and Ovx-Ris.  This data is similar to that found by 
Bagi, et al (1997) in their paper about femoral neck strength of estrogen deficient rats.  
The Ovx animals in their study had a significantly lower BMD at the end of their 
study (12 weeks), but the ultimate strength was not significantly different between the 
Normal and Ovx groups, but the Ovx group was significantly less stiff.  Crabtree et al 
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(2001) found that the main factor in hip fracture was cortical bone and not trabecular 
bone as it would have been thought.  The relatively slower change of the cortical bone 
in the rabbits could be a reason for the lack of difference in ultimate strength, even if 
stiffness may decrease, which could be due to architectural changes of the trabecular 
bone. 
8.4 Discussion of BMD testing of bones 
 
 The BMD in Group II found from DEXA were not significantly different 
between groups, but the BMD has a slight correlation with the fracture toughness 
values, but does not have a high level of significance.  The lack of significance could 
be from a lack of numbers, or there may not be a relationship, but the relationship has 
been well established, so it is likely the former and not the latter. 
 The BMC’s found by Ruthanne Cain, et al (2003) for Group III were not 
significantly different for any treatment group, which implies that the 140 day time 
period may not be long enough for a difference to be detected by the test.  The sample 
size may also be too small, since the beginning BMD is not known, and the lack of 
difference could be caused by chance, since the peak BMD for each animal differs. 
Lugero, et al (2000) using an overectomized rabbit model found no significant 
difference in  BMD in the rabbit tibia after 4 months, and believe this maybe from the 
particular R/F balance dynamic of the rabbit and the need for longer periods of time 
for the difference to manifest.  A guinea pig take approximately 6 months for a BMD 
difference to be found.  Cao, et al (2000) found no significant difference in cortical 
BMD after 4 and 12 weeks, but found a significant difference in trabecular bone 
mass. 
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8.5 Discussion of Weights 
 
 The body mass of the animal seems to be a very important parameter in 
considering the properties of the bones.  The animals in the Ovx groups gained a 
larger percentage of weight than their non-Ovx (intact) counterparts.  Estrogen 
deficiency causes a decrease in bone mineral density, through an increase in bone 
resorption.  Estrogen deficiency also cause and increase in body mass, which has 
been shown to cause an increase in bone mineral density.  For the Ovx control 
groups, the two effects on BMD may have been offsetting, such that the bone quality 
was not significantly different than that of the normal rabbit.  The Ovx animals 
treated with risedronate had the increase in body mass, which would cause an 
increase in BMD, but the drugs counteracts the increased resorption caused by 
estrogen deficiency, thus the net change in BMD is positive, since there is no negative 
change to cause a decrease in properties.  The changes are evident in the comparisons 
of fracture toughness, histomorphometric properties, and to some extent, the stiffness 
values from the femoral neck testing. 
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8.6 Limitations 
 
Limitations of this study include: 
1. The number of specimens is relatively low for the amount of scatter in the data.  A 
larger sample size may bring about significance. 
2. The effects of machining on the fracture toughness of the specimens is not known.  
The methodology of machining is the same for each specimen, so it should not effect 
results for the comparison within groups. 
3. The specimens do not satisfy all of the ASTM requirements for fracture toughness 
test specimens, so they cannot be compared to other engineering materials. 
4. A razor blade was used to initiate the precrack.  The use of the razor blade to initiate 
the crack may affect toughness, and this type of crack may not be seen in vivo. 
5. The period of time (20 weeks) may not have been sufficiently long to be able to see 
mechanical differences between treatment groups. 
6. Bone Mineral Density was not tested at the beginning of the experiment.  The final 
BMD may or may not have changed, and the peak density could have affected the 
outcome. 
7. Blood and/or urine samples were never taken for testing of Calcium levels as a 
marker of bone turnover. 
8. No dynamic histomorphometry of these bones were performed.  The successful use of 
markers could give insight into the mechanisms of estrogen deficiency and drug 
treatment on resorption and formation. 
9. The body composition and its change with ovariectomy and time are not known 
10. The levels of circulating hormones were never measured. 
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11. No cancellous bone histomorphometry was performed to perhaps explain some of the 
femoral neck fracture data. 
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8.7 Recommendations for Future Study 
 Although this study has expanded the knowledge of the use of an 
ovarectomized rabbit model, and in the testing of bone specimens from said model, 
other relationships and causes for observations should be investigated.  Some 
suggestions for future investigation include, but not limited to: 
1. Analyze the biochemical parameters of the tibia and femur.  Some of the 
differences in fracture toughness may be do to the collagen makeup.  
Biochemical analysis may also lend insight to the effect of bisphosphonates 
on the rabbit bone physiology. 
2. Investigate other machining methods.  Care and research went into the design 
of the machining procedure, but this does not mean that the technique is 
perfected. 
3. Dynamic histomorphometry should be performed.  Dynamic 
histomorphometry would allow for the study of mineralization rates, and their 
effect on fracture toughness. 
4. Bone mineral density should be measured at the beginning of the experiment 
to investigate BMD change and the changes effect on fracture toughness. 
5. Characterize the femoral neck and head geometry.  The archetetural of the 
head and neck region could have a major effect on the strength and rigidity of 
the structure. 
6. Determine clinical applications for predicting fracture in humans. 
7. Use varying lengths of time for testing, including tests of longer duration to 
determine the change in fracture toughness with time after ovarectomy. 
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8. Investigate the blood hormone levels, since estrogen is an important hormone, 
but it is not the only regulating hormone. 
9. Measure the body composition of the animals, and determine if this has an 
effect on the fracture toughness, and/or the circulating levels of hormones. 
10. Perform histomorphometry of the trabecular bone, to determine if the change 
effects the femoral neck fracture results. 
11. Investigate other material tests, including other fracture modes, and whole 
bone tests, such as three point bending.  
12. Fracture toughness of Ovx and Ovx-Ris bone should be investigated in other 
directions, besides just the longitudinal direction, since the bone fibers may be 
reorienting themselves with the new loading enviroment. 
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8.8 Contributions 
 
This study contributed to the expanding knowledge of fracture toughness of 
estrogen and drug treated rabbits in the following ways. 
1. There is a correlation between the compliance and the body mass of the animal. 
2. There seems to be a relationship between fracture type and body mass. 
3. Various testing procedures were standardized, which could allow future testing. 
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APPENDIX A: H & E STAINING PROCEDURE 
 
This procedure is for H & E staining of plastic embedded bone sections of 80 
– 100 µm, that have been subsequently ground and polished to a final thickness of 
~50 µm. 
The section is first rinsed in water, and then allowed to soak in Harris’ 
Hematoxylin for 15 minutes on a platform shaker at 95 rpm.  The section is then 
placed in gently running water for five minutes.  After the rinse, the section is dipped 
gently 20 times in Acid Alcohol, which is a solution of 10 ml HCL to 1990 mL of 
distilled water.  The specimen is then placed in a running water rinse for 8 minutes.  
The specimen is then dipped gently 15 times in Ammonia Water, which is a solution 
of 3 mL ammonium hydroxide to 1000 mL tap water.  The specimen is again placed 
in a running water rinse for 15 minutes.  After the rinse, the specimen soaked in Eosin 
for 6 minutes.  After the Eosin bath, the specimen goes through a series of dipping in 
order 80% Alcohol, 95% Alcohol, 100% Alcohol, 100% Alcohol, Xylene for 10, 15, 
15, 15, and 15 dips respectively. 
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APPENDIX B: PLASTIC EMBEDDING PROCEDURE 
Introduction: 
Microscopic investigation necessitates the thin sectioning of the material that 
is desired to be studied.  The problem of sectioning is multifaceted, since often the 
material sample, although large by microscope terms, is much too small for 
conventional machining techniques.  Fragility of the structures, which are desired for 
investigation, also pose a problem, since these can be destroyed during the sectioning 
process. 
Plastic embedding of the material is one way that these limitations can be overcome.  
The plastic gives support to the sectioned structures, which helps keep them from 
being destroyed, and it gives extra length and width such that the specimen can be 
clamped and sectioned. 
Procedure: 
 
1. Specimens are fixed in 10% neutral buffered formalin. 
2. The specimens are place in a Hypercenter XP tissue processor (Shandon, 
Pittsburgh, PA) for processing which includes: 
a. Dehydration in alcohol 
b. Clearing with Xylene 
c. Infiltration with methymethacrylate (MMA) 
3. Specimens are embedded in MMA (100 ml MMA to 0.2 g Perkadox) 
4. Specimens are left in vacuum oven for 1-2 hours to remove air bubbles 
5. Specimens are place in water bath (36 oC) overnight for polymerization
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APPENDIX C: MMA EMBEDDED CROSS-SECTION POLISHING PROCEDURE 
 
 
Gently pick up the 
specimen, and dip 
it in a beaker #1 of 
distilled water 5 
times, then beaker 
#2 of distilled 
water 5 more times.
4. Put the specimen on the nylon cloth.  Spray 
2-3 drops of 3 micron polishing solution 
(green) on the cloth.  Polish using circular 
motion.  Polish for 6 minutes, turning three 
times (every 2 mins). 
5. Put the specimen on the second nylon 
cloth.  Spray 2-3 drops of 1 micron polishing 
solution (blue) on the cloth.  Polish with 
circular motions.  Polish for 4 minutes.  Turn 
over three times (1min 20 sec per side). 
6. Put the specimen on the microcloth, spray 
with a few drops of distilled water.  Polish 
with circular motions for 2 mins., turning over 
once (1 min per side). 
7. Dry the specimen on a napkin for approximately five minutes.  Check on the 
microscope 40x to make sure there are no scratches.  If there are scratches 
repeat steps three through five.  If there are not scratches mount on a slide 
labeled with the specimen number with flourmount and cover slip.  If it is to be 
stained, place the specimen back in the cassette and store in a small beaker of 
distilled water. 
1. Cut Sections From Plastic Embedded Bone.  Make the cuts at 45 marks 
(450 µm), which will give a final thickness of 120 µm.
2. Store the sections in plastic cassettes labeled with the specimen number 
in a large beaker of distilled water.
3. Use forceps to pick up the specimen and 
gently place on the 800# sandpaper.  Spray a 
small puddle of distilled on the sand paper.   
Begin polishing circular motion, add some 
pressure.  Keep polishing for four mins.  Turn 
over three times (1 min 20 sec per side).
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APPENDIX D: IN-VIVO STAIN PREPARATION 
Two different stains were used in this study for the purpose of dynamic 
histomorphometry, tetracycline and Calcein. 
 
Tetracycline: 
 
1. Mix 2.5 grams of powdered tetracycline in 100 ml of phosphorous buffered saline 
(PBS). 
2. Stir using magnetic stirrer for several minutes (15 – 30 mins). 
3. Use buffers to bring the pH to normal biological level (7.4).  Note: This step is very 
important, because tetracycline is very acidic. 
4. Using filters put the solution into sterile vials. 
5. Refrigerate (4 oC) until used. 
6. Dosing is give in the same manner as the risedronate 1ml/kg  
7. Injections can be given subcutaneously or intraperitoneally. 
 
Calcein: 
1. Make 100 ml of 2% sodium bicarbonate and distilled water (2 mg NaH2CO3 in 100 
ml of distilled water). 
2. Mix 1.5 grams of powdered calcein in 100 ml of the solution made in step 1. 
3. Stir using a magnetic stirrer for several minutes (15-30 mins). 
4. Using filters put the solution into sterile vials 
5. Refrigerate (4 oC) until used 
6. Dosing is given in the same manner as the risedronate 1 ml/kg. 
7. Injections can be given subcutaneous or intraperitoneal. 
 
 
 
